Cardio Diagnostics Holdings, Inc Receives Innovative Technology Contract From Vizient For Its Novel AI-Driven Precision Heart Disease Tests – Epi+Gen CHD & PrecisionCHD
Portfolio Pulse from Benzinga Newsdesk
Cardio Diagnostics Holdings, Inc (NASDAQ:CDIO) has been awarded an Innovation Technology contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the US. The contract is for Cardio Diagnostics' AI-driven molecular heart disease tests, Epi+Gen CHD and PrecisionCHD, which identify epigenetic and genetic biomarkers in patients at risk of coronary heart disease. The contract will be effective from November 1.
October 31, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardio Diagnostics has secured a contract with Vizient for its AI-driven heart disease tests. This could increase the company's market reach and potentially boost its revenues.
The contract with Vizient, a major player in the healthcare industry, could significantly increase the reach of Cardio Diagnostics' products. This could lead to increased sales and revenues for the company, potentially boosting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100